Advertisement

21st International AIDS Conference (AIDS 2016)

News

Selected Publications Launched at AIDS 2016

August 9, 2016

 1  |  2  |  Next > 

As with other World AIDS Conferences, many organisations used the meeting to launch publications. A selection of these are highlighted below.


Spotlight: AIDS Durban 2000-2016

TAC and Section27

Compulsive reading from some of the sharpest and most inspiring activists involved in the South African struggle report on the historical context of the Durban conference.

This is a joint publication from Treatment Action Campaign and Section27.

Spotlight: A print and online publication monitoring South Africa's response to TB and HIV, the state of our health systems and the people that use it and keep it going. First edition, July 2016.
www.spotlightnsp.co.za
www.spotlightnsp.co.za/wp-content/uploads/2016/07/000-spotlight-15-web.pdf (PDF)


Untangling the Web of Antiretroviral Price Reductions

Untangling the Web of Antiretroviral Price Reductions

Médecins Sans Frontières (MSF)/Doctors Without Borders

The 18th edition of the MSF HIV drug pricing report is the single most important reference for pricing and access to generic HIV drugs globally.

This update is one of the clearest reports for tracking the importance of generic competition, primarily from India.

Since the last edition, the lowest available price for a WHO-recommended first-line one-pill-a-day ART (tenofovir/emtricitabine/efavirenz) had dropped by 26% from $136 to US$100 per person per year. For second-line ART, the lowest available price has dropped 11% from $322 to $286 (zidovudine/lamivudine + atazanavir/ritonavir).

Newer drugs remain far higher but are the only options for third-line ART. The lowest annual price for raltegravir + darunavir/ritonavir + etravirine is $1,859, reduced by only 7% from $2,006 per year in 2014. This is more than 18 times the price of first-line therapy, and more than six times the price of today's most affordable second-line combination.

The report also highlights the growing concern for access to ART middle-income countries who pay much higher prices for these medicines because of pharmaceutical patents.

www.doctorswithoutborders.org/article/msf-report-shows-price-newer-hiv-medicines-18-times-more-expensive-first-line-treatment

www.doctorswithoutborders.org/sites/usa/files/antiretroviral_price_reductions.pdf (PDF)


Making Viral Load Routine

Making Viral Load Routine

Médecins Sans Frontières (MSF)/Doctors Without Borders

Based on a survey from ten ART sites and seven viral load testing labs this MSF report aims to share practical lessons from the field with Ministries of Health and implementing partners.

The two-part report covers the strategies required within the clinic (for clinicians, counsellors and patients) and the realities of both setting up and keeping a viral load testing laboratory functional in low-income settings.

It emphasises that national viral load scale up plans must link both programmatic and laboratory planning if viral load tests are to become a routine part of HIV care.

www.msfaccess.org/content/report-making-viral-load-routine


TRANSIT: UNAIDS Report on Care for Transgender People

UNDP

This report from the United Nations Development Programme (UNDP) was launched in a few months before AIDS 2016 but the conference provided one of the first chances to widely distribute this toolkit on transgender issues.

"Implementing comprehensive HIV and STI programmes with transgender people: practical guidance for collaborative interventions" is a resource that was developed by a broad network of trans people, programme managers, researchers and development partners.

TRANSIT: UNAIDS Report on Care for Transgender People

Running to almost 200 pages it is written in five main sections.

  1. Community empowerment. The foundation of the resource, describes how empowerment of trans people is both an intervention in itself, and also essential to effective planning, implementation and monitoring of all aspects of HIV and STI prevention, diagnosis, treatment and care.
  2. Stigma, discrimination, violence and human rights. The urgent needs of trans people: to be protected from violence, discrimination and other forms of human-rights violation.
  3. Services. Detailed descriptions of gender-affirming health services and HIV-related and other essential health interventions. These include primary care, cross-sex hormone therapy, surgical procedures and service integration. HIV-related services include condom and lubricant programming, harm reduction services for substance use and safe injection, pre- and post-exposure prophylaxis, voluntary HIV testing, antiretroviral therapy, sexual and reproductive health, and mental and psychosocial health. The chapter also addresses HIV and hormonal therapy.
  4. Service delivery. Trans-competent clinical approaches, social and behavioural interventions, approaches to HIV prevention, community-led service delivery, safe spaces (drop-in centres), and the use of information and communication technologies.
  5. Programme management. Practical guidance on planning, starting, scaling up, managing and monitoring both large multi-site programmes and more localised organisations.

www.undp.org/content/undp/en/home/librarypage/hiv-aids/implementing-comprehensive-hiv-and-sti-programmes-with-transgend.html

www.unfpa.org/sites/default/files/pub-pdf/TRANSIT_report_UNFPA.pdf (PDF)

 1  |  2  |  Next > 


Related Stories

What Would an HIV Cure Mean for You?
Charlize Theron's 8 Quotable Moments About HIV at AIDS 2016
Plants, PrEP Posters and People: The Research Literacy Networking Zone at AIDS 2016



This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.